• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国囊性纤维化注册研究中的挽救治疗:对成年 CF 患者静脉用抗生素使用的预测因素的探讨。

Rescue therapy within the UK Cystic Fibrosis Registry: An exploration of predictors of intravenous antibiotic use amongst adults with CF.

机构信息

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK.

Sheffield Adult CF Centre, Northern General Hospital, Sheffield, UK.

出版信息

Respirology. 2018 Feb;23(2):190-197. doi: 10.1111/resp.13174. Epub 2017 Sep 14.

DOI:10.1111/resp.13174
PMID:28905459
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5813205/
Abstract

BACKGROUND AND OBJECTIVE

Intravenous (i.v.) antibiotics are needed for rescue when preventative therapy fails to achieve stability among adults with cystic fibrosis (CF). Understanding the distribution of i.v. days can provide insight into the care that adults with CF need. We aim to determine the baseline characteristics that are associated with higher i.v. use, in particular to test the hypothesis that prior-year i.v. use is associated with future-year i.v. use.

METHODS

This is a cross-sectional analysis of the 2013-2014 UK CF registry data. Stepwise logistic regression was performed using current-year i.v. days as the dependent variable, and demographic variables including prior-year i.v. days as the covariates. Based on these results, study sample was divided into clinically meaningful subgroups using analysis similar to tree-based method.

RESULTS

Data were available for 4269 adults in 2013 and 4644 adults in 2014. Prior-year i.v. use was the strongest predictor for current-year i.v. use followed by forced expiratory volume in 1 s (FEV ). Adults with high prior-year i.v. use (>14 days) continued to require high levels of i.v., regardless of FEV . Those with high prior-year i.v. use and FEV ≥70% had higher current-year i.v. days compared to adults with low prior-year i.v. use and FEV <40% (28 days, interquartile range (IQR): 11-41 days vs 14 days, IQR: 0-28 days; Mann-Whitney P-value <0.001 in 2013).

CONCLUSION

CF people with prior high levels of rescue often continue to need high levels of rescue even if they have good FEV . The reasons for this require further investigations.

摘要

背景和目的

对于患有囊性纤维化(CF)的成年人,如果预防治疗未能达到稳定,就需要静脉(i.v.)抗生素进行抢救。了解静脉天的分布情况可以深入了解 CF 成年人所需的护理。我们旨在确定与更高的静脉使用率相关的基线特征,特别是测试前一年静脉使用率与未来一年静脉使用率相关的假设。

方法

这是对 2013-2014 年英国 CF 登记处数据的横断面分析。使用当前年度静脉天作为因变量,逐步逻辑回归,将人口统计学变量(包括前一年静脉天)作为协变量。基于这些结果,使用类似于基于树的方法的分析,将研究样本分为具有临床意义的亚组。

结果

2013 年有 4269 名成年人和 2014 年有 4644 名成年人的数据可用。前一年的静脉使用率是当前年度静脉使用率的最强预测因素,其次是 1 秒用力呼气量(FEV )。高前一年静脉使用率(>14 天)的成年人继续需要高水平的静脉,无论 FEV 如何。与低前一年静脉使用率和 FEV <40%的成年人相比,高前一年静脉使用率和 FEV ≥70%的成年人当前年度静脉天数更高(28 天,四分位距(IQR):11-41 天比 14 天,IQR:0-28 天;2013 年 Mann-Whitney P 值<0.001)。

结论

即使 FEV 良好,先前高水平急救的 CF 患者往往仍需要高水平的急救。需要进一步调查这种情况的原因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/5813205/cf2becea68e5/RESP-23-190-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/5813205/8a42b139f83a/RESP-23-190-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/5813205/915e3bd37441/RESP-23-190-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/5813205/cf2becea68e5/RESP-23-190-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/5813205/8a42b139f83a/RESP-23-190-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/5813205/915e3bd37441/RESP-23-190-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/5813205/cf2becea68e5/RESP-23-190-g003.jpg

相似文献

1
Rescue therapy within the UK Cystic Fibrosis Registry: An exploration of predictors of intravenous antibiotic use amongst adults with CF.英国囊性纤维化注册研究中的挽救治疗:对成年 CF 患者静脉用抗生素使用的预测因素的探讨。
Respirology. 2018 Feb;23(2):190-197. doi: 10.1111/resp.13174. Epub 2017 Sep 14.
2
Do cystic fibrosis centres with the lowest FEV still use the least amount of intravenous antibiotics? A registry-based comparison of intravenous antibiotic use among adult CF centres in the UK.低 FEV 的囊性纤维化中心是否仍使用最少的静脉抗生素?英国成人 CF 中心基于注册的静脉抗生素使用比较。
J Cyst Fibros. 2018 May;17(3):360-367. doi: 10.1016/j.jcf.2017.10.005. Epub 2017 Oct 23.
3
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.用于囊性纤维化患者肺部加重期的静脉用抗生素
Cochrane Database Syst Rev. 2025 Jan 20;1(1):CD009730. doi: 10.1002/14651858.CD009730.pub3.
4
Antibiotic duration and changes in FEV are not associated with time until next exacerbation in adult cystic fibrosis: a single center study.抗生素疗程和 FEV 变化与成人囊性纤维化下一次加重的时间无关:一项单中心研究。
BMC Pulm Med. 2017 Nov 29;17(1):160. doi: 10.1186/s12890-017-0503-6.
5
Intravenous antibiotic use and exacerbation events in an adult cystic fibrosis centre: A prospective observational study.静脉用抗生素与成人囊性纤维化中心的恶化事件:一项前瞻性观察研究。
Respir Med. 2019 Jul-Aug;154:109-115. doi: 10.1016/j.rmed.2019.06.017. Epub 2019 Jun 18.
6
Macrolide antibiotics (including azithromycin) for cystic fibrosis.大环内酯类抗生素(包括阿奇霉素)治疗囊性纤维化。
Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD002203. doi: 10.1002/14651858.CD002203.pub5.
7
Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.口服阿奇霉素治疗与静脉用妥布霉素或黏菌素治疗对囊性纤维化成人肺部恶化后肺功能恢复的影响。
Ann Am Thorac Soc. 2019 Jul;16(7):853-860. doi: 10.1513/AnnalsATS.201811-773OC.
8
Daily spirometry in an acute exacerbation of adult cystic fibrosis patients.成人囊性纤维化患者急性加重期的每日肺功能测定。
Chron Respir Dis. 2018 Aug;15(3):258-264. doi: 10.1177/1479972317743756. Epub 2017 Nov 28.
9
Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.依伐卡托起始治疗后的真实世界结局纵向趋势:来自爱尔兰囊性纤维化注册研究的队列研究。
Ann Am Thorac Soc. 2019 Feb;16(2):209-216. doi: 10.1513/AnnalsATS.201802-149OC.
10
Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience.门诊囊性纤维化肺部加重期管理中口服抗菌药物的应用:单中心经验
Clin Respir J. 2012 Jan;6(1):56-64. doi: 10.1111/j.1752-699X.2011.00246.x. Epub 2011 Aug 9.

引用本文的文献

1
Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.依伐卡托-替扎卡托-艾列卡托、替扎卡托-依伐卡托和鲁玛卡托-依伐卡托治疗囊性纤维化:系统评价与经济学评估
Health Technol Assess. 2025 May;29(19):1-111. doi: 10.3310/CPLD8546.
2
Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial.自我管理干预通过支持治疗依从性来减少成人囊性纤维化患者的肺部恶化:一项随机对照试验。
Thorax. 2022 May;77(5):461-469. doi: 10.1136/thoraxjnl-2021-217594. Epub 2021 Sep 23.
3

本文引用的文献

1
Physiologic endpoints for clinical studies for cystic fibrosis.囊性纤维化临床研究的生理终点。
J Cyst Fibros. 2016 Jul;15(4):416-23. doi: 10.1016/j.jcf.2016.05.014. Epub 2016 Jun 15.
2
Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence".准确报告成年囊性纤维化患者吸入疗法的依从性:计算“规范依从性”的方法
Patient Prefer Adherence. 2016 May 23;10:887-900. doi: 10.2147/PPA.S105530. eCollection 2016.
3
The Dynamics of Disease Progression in Cystic Fibrosis.
Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study.
支持成人囊性纤维化患者服药依从性的随机可行性研究。
BMC Pulm Med. 2019 Apr 11;19(1):77. doi: 10.1186/s12890-019-0834-6.
囊性纤维化疾病进展的动态变化
PLoS One. 2016 Jun 1;11(6):e0156752. doi: 10.1371/journal.pone.0156752. eCollection 2016.
4
Variable selection with stepwise and best subset approaches.逐步法和最佳子集法的变量选择。
Ann Transl Med. 2016 Apr;4(7):136. doi: 10.21037/atm.2016.03.35.
5
Cystic fibrosis.囊性纤维化。
Lancet. 2016 Nov 19;388(10059):2519-2531. doi: 10.1016/S0140-6736(16)00576-6. Epub 2016 Apr 29.
6
Dornase alfa for cystic fibrosis.用于囊性纤维化的重组人脱氧核糖核酸酶
Cochrane Database Syst Rev. 2016 Apr 4;4:CD001127. doi: 10.1002/14651858.CD001127.pub3.
7
Aerosolized Antibiotics for Patients with Bronchiectasis.支气管扩张症患者的雾化抗生素
Am J Respir Crit Care Med. 2016 Apr 1;193(7):808-10. doi: 10.1164/rccm.201507-1449LE.
8
Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets.囊性纤维化中的气道表面液体动态平衡:病理生理学和治疗靶点。
Thorax. 2016 Mar;71(3):284-7. doi: 10.1136/thoraxjnl-2015-207588. Epub 2015 Dec 30.
9
IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.前一年接受静脉治疗的肺部加重:囊性纤维化患者未来肺部加重的一个重要独立危险因素。
J Cyst Fibros. 2016 May;15(3):372-9. doi: 10.1016/j.jcf.2015.10.006. Epub 2015 Oct 23.
10
Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function.一秒用力呼气容积变异性有助于识别有肺功能更大丧失风险的囊性纤维化患者。
J Pediatr. 2016 Feb;169:116-21.e2. doi: 10.1016/j.jpeds.2015.08.042. Epub 2015 Sep 19.